Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Elicio Therapeutics Inc ELTX

Healthcare Biotechnology
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph... see more

Current News (NDAQ:ELTX)

Elicio Therapeutics Reports Inducement Grants

GlobeNewswire 8 days ago

Elicio Therapeutics Reports Inducement Grants

GlobeNewswire December 16, 2025

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

GlobeNewswire December 11, 2025

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

GlobeNewswire November 19, 2025

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

GlobeNewswire November 13, 2025

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

GlobeNewswire November 7, 2025

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

GlobeNewswire November 3, 2025

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

GlobeNewswire October 27, 2025

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

GlobeNewswire September 29, 2025
View More News ››

Opinion & Analysis (NDAQ:ELTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ELTX)

Using technical analysis for this stock.

It is starting to climb up from the low share prices and it's looking good for shareholders
coolfooldumbguy - August 18, 2025

Elicio Therapeutics (NASDAQ:ELTX): Pioneering Lymph Node-Tar

https://beyondspx.com/article/elicio-therapeutics-nasdaqeltx-pioneering-lymph-node-targeted-immunotherapies-for-cancer-patients
MikeTester - January 22, 2025
View more Bullboard ››

Grizzly Discoveries Inc

Grizzly Discoveries Inc

Grizzly Discoveries Inc. engages in the acquisition, exploration, and development of precious and base metals properties ...
View More »

Podcasts